Irland - engelsk - HPRA (Health Products Regulatory Authority)

parke davis & company - levobunolol - 0.5 per cent

Irland - engelsk - HPRA (Health Products Regulatory Authority)

parke davis & company - levobunolol - 1 per cent

USA - engelsk - NLM (National Library of Medicine)

parke-davis div of pfizer inc - phenytoin sodium (unii: 4182431bjh) (phenytoin - unii:6158tkw0c5) - phenytoin sodium 30 mg - dilantin is indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. dilantin is contraindicated in patients with: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), such as dilantin, during pregnancy. physicians are advised to recommend that pregnant patients taking dilantin enroll in the north american antiepileptic drug (naaed) pregnancy registry. this can be done by calling the tollfree number 1-888-233-2334, and must be done by patients themselves. information on the registry can also be found at the website http://www.aedpregnancyregistry.org/ risk summary in humans, prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. prenatal phenytoin exposure is associated with an increased incidence of major malformations, inc

USA - engelsk - NLM (National Library of Medicine)

parke-davis div of pfizer inc - phenytoin (unii: 6158tkw0c5) (phenytoin - unii:6158tkw0c5) - phenytoin 125 mg in 5 ml - dilantin is indicated for the treatment of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures. dilantin is contraindicated in patients with: - a history of hypersensitivity to phenytoin, its inactive ingredients, or other hydantoins [see warnings and precautions (5.5)]. reactions have included angioedema. - a history of prior acute hepatotoxicity attributable to phenytoin [see warnings and precautions (5.8)]. - coadministration with delavirdine because of the potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), such as dilantin, during pregnancy. physicians are advised to recommend that pregnant patients taking dilantin enroll in the north american antiepileptic drug (naaed) pregnancy registry. this can be done by calling the tollfree number 1-888-233-233

USA - engelsk - NLM (National Library of Medicine)

parke-davis div of pfizer inc - phenytoin (unii: 6158tkw0c5) (phenytoin - unii:6158tkw0c5) - phenytoin 50 mg - dilantin infatabs are indicated for the treatment of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. dilantin is contraindicated in patients with: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), such as dilantin, during pregnancy. physicians are advised to recommend that pregnant patients taking dilantin enroll in the north american antiepileptic drug (naaed) pregnancy registry. this can be done by calling the tollfree number 1-888-233-2334, and must be done by patients themselves. information on the registry can also be found at the website http://www.aedpregnancyregistry.org/. risk summary in humans, prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. prenatal phenytoin exposure is associated with an increas

USA - engelsk - NLM (National Library of Medicine)

parke-davis div of pfizer inc - pregabalin (unii: 55jg375s6m) (pregabalin - unii:55jg375s6m) - pregabalin 82.5 mg - lyrica cr is indicated for the management of: efficacy of lyrica cr has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures. lyrica cr is contraindicated in patients with known hypersensitivity to pregabalin or any of its components. angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy [see warnings and precautions (5.1, 5.2), adverse reactions (6)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to pregabalin during pregnancy. to provide information regarding the effects of in utero exposure to lyrica cr, physicians are advised to recommend that pregnant patients taking lyrica cr enroll in the north american antiepileptic drug (naaed) pregnancy registry. this can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. information on the registry can also be found at the website h

USA - engelsk - NLM (National Library of Medicine)

parke-davis - chloramphenicol (unii: 66974fr9q1) (chloramphenicol - unii:66974fr9q1) - ointment - chloramphenicol should be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated. bacteriological studies should be performed to determine the causative organisms and their sensitivity to chloramphenicol (see boxed warning). chloromycetin ophthalmic ointment, 1% (chloramphenicol ophthalmic ointment, usp) is indicated for the treatment of surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms. the particular antiinfective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus streptococcus , including streptococcus pneumoniae escherichia coli haemophilus influenzae klebsiella/enterobacter species moraxella lucunata     (morax-axenfeld bacillus) neisseria species this product does not provide adequate coverage against: pseudomonas aeruginosa serratia marcescens this product is contraindicated in persons sensitive to any of its components.

USA - engelsk - NLM (National Library of Medicine)

parke-davis div of pfizer inc - pregabalin (unii: 55jg375s6m) (pregabalin - unii:55jg375s6m) - pregabalin 25 mg - lyrica is indicated for: lyrica is contraindicated in patients with known hypersensitivity to pregabalin or any of its components. angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy [see warnings and precautions (5.2)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to lyrica during pregnancy. to provide information regarding the effects of in utero exposure to lyrica, physicians are advised to recommend that pregnant patients taking lyrica enroll in the north american antiepileptic drug (naaed) pregnancy registry. this can be done by calling the toll free number 1-888-233-2334, and must be done by patients themselves. information on the registry can also be found at the website http://www.aedpregnancyregistry.org/. risk summary there are no adequate and well-controlled studies with lyrica in pregnant women. however, in animal reproduction studies, increased incidences of fetal structural abnor

USA - engelsk - NLM (National Library of Medicine)

parke-davis div of pfizer inc - phenelzine sulfate (unii: 2681d7p965) (phenelzine - unii:o408n561gf) - phenelzine 15 mg - nardil has been found to be effective in depressed patients clinically characterized as "atypical," "nonendogenous," or "neurotic." these patients often have mixed anxiety and depression and phobic or hypochondriacal features. there is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. nardil should rarely be the first antidepressant drug used. rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions. nardil should not be used in patients who are hypersensitive to the drug or its ingredients, with pheochromocytoma, congestive heart failure, severe renal impairment or renal disease, a history of liver disease, or abnormal liver function tests. the potentiation of sympathomimetic substances and related compounds by mao inhibitors may result in hypertensive crises (see warnings). therefore, patients being treated with nardil should not take sympathomimetic drugs (including amphetamines, co

USA - engelsk - NLM (National Library of Medicine)

parke-davis div of pfizer inc - methsuximide (unii: 0g76k8x6c0) (methsuximide - unii:0g76k8x6c0) - methsuximide 300 mg - celontin is indicated for the control of absence (petit mal) seizures that are refractory to other drugs. methsuximide should not be used in patients with a history of hypersensitivity to succinimides.